Specialty
A CVS Health Live episode focuses on improving cancer care by encouraging greater patient accessibility and lowering... More
Video
Insights provides context and perspective about key pharmacy trends and issues
Insights offers context and perspective about key pharmacy and health care topics.
Specialty
Research published by Coram shows that helping patients transition to at-home or ambulatory center infusion treatments can be beneficial to both patients and payors. More
Briefing
Specialty
Key drugs to watch for in the specialty pharmacy pipeline Q4 2018–Q1 2019 More
Specialty Report
Specialty
Treatment options for hemophilia continue to expand, which is good news for patients. Recently approved therapy options offer better outcomes but need careful management. More
Briefing
Specialty
CVS Health’s three-tier specialty formulary design separates the increasingly more expensive specialty therapies into three distinct copay or coinsurance categories. Paired with True... More
Briefing
Specialty
PAH is a rare, life-threatening disease, which is incurable. It is difficult to manage and to help ensure the longest survival and best possible quality of life, members need comprehensive... More
Briefing
Specialty
While the launch time is uncertain, potential PAH generics could give payors greater cost control opportunities for a complex, expensive condition requiring lifelong treatment. More
Briefing
Specialty
Learn more about how CVS Health plans to reshape kidney care by helping improve care and quality of life for patients with kidney disease. More
Video
Specialty
CVS Health is utilizing our integrated model and expertise in holistic patient care to an area of unmet clinical need — chronic kidney disease and end-stage renal disease – to reshape... More
Feature
Specialty
Kidney disease is highly prevalent and caring for members with kidney disease is highly complex and expensive. Learn more about this complex, expensive condition. More
Infographic
Specialty
Gene therapies bring hope for patients with conditions with few or no treatments, but also other considerations including safety and cost. More
Feature